Who Is Buying Intuitive Surgical? Hedge Fund Activity in 2026

Intuitive Surgical (ISRG) is the undisputed leader in robotic-assisted surgery, and its da Vinci surgical systems have become a fixture in operating rooms worldwide. With the stock trading around $452 per share, the question on every investor's mind is: are the biggest hedge funds buying or selling ISRG?

We analyzed the latest SEC 13F filings from 35 major hedge funds and institutional investors to answer that exact question. The verdict? Institutional sentiment for Intuitive Surgical is decisively bullish — with nearly half of all tracked funds increasing their positions.

ISRG Key Stats at a Glance

Out of 17 actively tracked funds holding ISRG, 8 are buying, 4 are selling, and 5 are holding steady. That's a 2:1 buy-to-sell ratio — a strong institutional endorsement for a stock at all-time highs.

Who's Buying Intuitive Surgical?

The buying side reads like a who's who of elite hedge funds. Multiple billion-dollar managers are adding significantly to their ISRG positions.

Vanguard leads all holders with a massive $15.2 billion position — and they're still increasing. When the world's largest asset manager keeps adding to a position of this size, it sends a clear signal about long-term conviction.

State Street holds $7.1 billion worth of ISRG and has also been adding shares. Fidelity rounds out the institutional titan trifecta with a $3 billion position that's been growing.

Among pure hedge funds, the buying is even more telling:

• Millennium Management — $672.2M (Increased). Israel Englander's multi-strategy giant has been aggressively building its ISRG position, making it one of their larger single-stock bets.
• Citadel Advisors — $470.4M (Increased). Ken Griffin's fund continues to add to what's already a substantial position.
• Coatue Management — $364.9M (Increased). Philippe Laffont's tech-focused fund sees robotic surgery as a secular growth story worth riding.
• Appaloosa Management — $54.1M (Increased). David Tepper adding to ISRG shows conviction from a famously selective value investor.
• Baker Bros Advisors — $28.6M (Increased). The healthcare-specialist fund is betting on continued surgical robotics adoption.

The combined buying from these funds represents over $1.5 billion in increased exposure to Intuitive Surgical — a powerful vote of confidence.

Who's Selling Intuitive Surgical?

While the buying side dominates, four funds have been trimming their ISRG positions:

• D.E. Shaw — $590.5M (Decreased). The quantitative giant still holds a substantial position but has been reducing. At nearly $600M, this remains a major holding even after trimming.
• Two Sigma — $207.9M (Decreased). Another quant fund taking profits, though the position size suggests they're far from bearish.
• Renaissance Technologies — $69.1M (Decreased). Jim Simons' legendary fund has pulled back modestly.
• Bridgewater Associates — $5M (Decreased). Ray Dalio's fund holds only a token position and has reduced further.

An interesting pattern emerges: the sellers are predominantly quantitative funds. D.E. Shaw, Two Sigma, and Renaissance are all quant-driven operations that tend to take profits systematically. This looks more like position management than a bearish call on the company's fundamentals.

Notable Moves

The most striking aspect of ISRG's institutional activity is the breadth of buying. When Millennium, Citadel, and Coatue are all increasing simultaneously, it suggests multiple different investment strategies — multi-strat, fundamental, and tech-focused — are all reaching the same conclusion: Intuitive Surgical is worth owning.

Five funds are maintaining steady hold positions, adding stability to the shareholder base. The lack of any complete exits is also notable — nobody is abandoning ship.

Appaloosa's increased position deserves special mention. David Tepper is known for concentrated, high-conviction bets. His decision to add ISRG to the portfolio suggests he sees meaningful upside even at current valuations.

What This Signals for ISRG Investors

The institutional picture for Intuitive Surgical is clearly bullish. Here's what the data tells us:

The bull case is strong. An 8-to-4 buy-sell ratio with major funds like Millennium ($672M) and Citadel ($470M) increasing is a robust signal. These funds have armies of analysts, proprietary data, and sophisticated models — and they're all saying "buy more."

Sellers are profit-taking, not fleeing. The selling funds are quant-oriented shops that regularly rotate positions. D.E. Shaw still holds nearly $600M — that's not bearish behavior. It's systematic rebalancing.

Healthcare specialists are bullish. Baker Bros, which focuses exclusively on healthcare and biotech, increasing their position adds sector-specific validation to the thesis.

Valuation isn't deterring smart money. At $452 per share, ISRG isn't cheap by any traditional metric. Yet institutional buyers are adding aggressively, suggesting they see the robotic surgery market as still early in its adoption curve.

The da Vinci platform's installed base continues to grow, procedure volumes are climbing, and the razor-and-blade business model (systems + instruments + services) generates recurring revenue that institutional investors love. Each system placed generates years of high-margin instrument and service revenue — a business model that funds like Millennium and Citadel find particularly attractive because of its predictability.

With competitors still years behind, ISRG's moat appears wide enough to justify premium pricing. The recent launch of the da Vinci 5 system adds another growth vector, with early adoption metrics reportedly exceeding internal expectations. This next-generation platform could accelerate the replacement cycle and expand into new surgical specialties.

The convergence of robotic surgery with AI-powered surgical assistance also positions Intuitive Surgical at the intersection of two major investment themes — healthcare innovation and artificial intelligence. This dual narrative likely explains why both healthcare-focused funds (Baker Bros) and tech-oriented managers (Coatue) are increasing simultaneously.

For individual investors, the message from Wall Street's biggest players is clear: Intuitive Surgical remains a core holding in institutional portfolios, and the smart money is still accumulating.

Track ISRG Institutional Activity in Real Time

Want to know the moment a major fund changes its ISRG position? Track ISRG institutional moves in real-time with Freenance Smart Money — we track 35 funds with $21.4T total AUM across 77,111 positions.

👉 app.freenance.io/smart-money/ticker/ISRG

Don't wait for the next 13F filing deadline to find out what hedge funds are doing. Freenance Smart Money gives you institutional-grade insights the moment they become available — so you can make informed decisions about your portfolio, not guesses.

Related Articles

• Who Is Buying NVIDIA? Hedge Fund Activity in 2026
• Who Is Buying Apple? Hedge Fund Activity in 2026
• Who Is Buying Tesla? Hedge Fund Activity in 2026

FAQ

Why are hedge funds buying Intuitive Surgical (ISRG)?

The 13F data shows an 8-to-4 buy-sell ratio across 17 tracked funds, including increases from Vanguard ($15.2B), Millennium, Citadel, and Coatue. Institutions appear to favor the razor-and-blade economics of the da Vinci platform — system placements drive years of high-margin instrument and service revenue. Healthcare specialist Baker Bros also added, providing sector-specific validation.

What role does da Vinci 5 play in the institutional thesis?

The next-generation da Vinci 5 platform expands surgical capability and is expected to accelerate the replacement cycle within Intuitive's installed base. For institutions, this adds a fresh growth vector on top of procedure volume expansion. Early adoption metrics have reportedly tracked above internal targets.

Are the funds selling ISRG bearish on the company?

Most sellers — D.E. Shaw, Two Sigma, Renaissance — are quantitative shops trimming systematically rather than abandoning the thesis. D.E. Shaw still holds nearly $600M after trimming, which suggests profit-taking and rebalancing, not a change in fundamental view. No tracked fund has exited entirely.

Why does ISRG's high valuation not deter institutional buyers?

Despite a premium multiple, funds are adding because they view robotic surgery as early in its adoption curve, with a wide moat protected by surgeon training, instrument lock-in, and regulatory hurdles. The recurring revenue base also commands a higher multiple than typical hardware businesses. Whether the valuation is justified remains an open question for any individual investor.

What does Coatue and Baker Bros buying together indicate?

Coatue is technology-focused while Baker Bros is healthcare-focused, so simultaneous accumulation means two different investment lenses see Intuitive Surgical as attractive. Robotic surgery sits at the intersection of healthcare innovation and AI-driven automation, which appeals to both mandates. This page is informational only and not investment advice.